RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Bengbu Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT03219593, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 65 years to Not stated; sex: all

    Registered eligibility fields

  2. Patients with histologically proven primary locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma;

    Inclusion criterion 1

  3. ECOG Performance Status: 0-2;

    Inclusion criterion 3

  4. At least one measurable lesion as defined by RECIST 1.1;

    Inclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT03219593, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients with histologically proven primary locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma;
  • Age ≥ 65 years;
  • ECOG Performance Status: 0-2;
  • No previous anti-cancer therapy for the locally advanced or metastatic disease;
  • Unable or unwilling to chemotherapy;
  • At least one measurable lesion as defined by RECIST 1.1;
  • With acceptable hematologic, cardiac, hepatic, pulmonary and renal function;
  • Can take apatinib orally;
  • Life Expectancy: 3 months or more.

Exclusion Criteria:

  • History of other primary malignancy (except basal cell skin cancer or cervical carcinoma in situ);
  • Patients with un-controlled blood pressure on medication (> 140/90 mmHg);
  • Patients with other nonmeasurable disease such as un-controlled diabetes, severe cardiovascular and cerebrovascular diseases;
  • Patients with bleeding tendency, receiving thrombolytics or anticoagulants;
  • Patients with massive hydrothorax or ascites;
  • Patients with uncontrolled central nervous system (CNS) metastases;
  • Proteinuria 2+ or 24-hour urinary protein ≥ 1g;
  • History of drug addiction or abuse;
  • Patients cannot take apatinib orally for any reason;
  • Estimated life expectancy ˂ 3 months;
  • Current, recent (within 4 weeks prior to study entry), or planned participation in any other clinical trials;
  • Inability to understand and agree to informed consent.

Quoted from ClinicalTrials.gov, NCT03219593, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT03219593, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT03219593